Business Context and Reporting Period
This Form 8-K reports on the virtual 2021 Annual Meeting of Stockholders held by PMV Pharmaceuticals, Inc. on June 2, 2021. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market under the symbol PMVP.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Shareholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Directors
- Thilo Schroeder, Ph.D.: Elected with 31,591,645 votes FOR, 4,507,250 WITHHELD, and 1,028,013 BROKER NON-VOTES.
- Peter Thompson, M.D.: Elected with 30,463,333 votes FOR, 5,635,562 WITHHELD, and 1,028,013 BROKER NON-VOTES.
- Both directors were elected to serve until the 2024 Annual Meeting.
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- Shareholders ratified the selection of Ernst & Young LLP for the fiscal year ending December 31, 2021.
- Voting results: 37,069,556 FOR, 57,272 AGAINST, and 80 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For further details on the proposals, the company refers investors to the definitive proxy statement on Schedule 14A filed on April 23, 2021.
Investor Verification Checklist
- Verify the term length for the newly elected Class I Directors (through 2024).
- Confirm the appointment of Ernst & Young LLP as the independent auditor for the 2021 fiscal year.
- Review the Schedule 14A proxy statement filed on April 23, 2021, for detailed background on the proposals.